Back to Journals » Clinical Ophthalmology » Volume 6

Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma

Authors Januleviciene I, Derkač I, Grybauskiene L, Paulauskaitė R, Gromnickaite R, Kuzmienė L

Received 9 November 2011

Accepted for publication 7 December 2011

Published 12 January 2012 Volume 2012:6 Pages 103—109


Review by Single anonymous peer review

Peer reviewer comments 2

Ingrida Januleviciene, Irmante Derkac, Lina Grybauskiene, Ruta Paulauskaite, Ruta Gromnickaite, Loreta Kuzmiene
Eye Clinic of Kaunas Medical Academy of Lithuanian University of Health Sciences, Kaunas, Lithuania

Purpose: To compare the effects on tolerability, tear osmolarity, and intraocular pressure (IOP)-lowering effect of switching from benzalkonium chloride (BAK) containing prostaglandin analog (PGA) latanoprost to preservative-free tafluprost.
Patients and methods: Thirty patients with open-angle glaucoma (N = 60 eyes), 26 women (87%) and four men (13%) aged 64.1 (SD 14.1) years, showing abnormal values of tear osmolarity, corneal fluorescein staining, tear film break-up time (TBUT), or subjective discomfort with current latanoprost treatment were included. After tear osmolarity (TearLab™ Osmolarity System), TBUT, corneal fluorescein staining, and baseline IOP (Goldmann tonometer) measurements and the completion of Ocular Surface Disease Index and Ocular Surface Symptoms in Glaucoma Scale questionnaires, patients were assigned to preservative-free tafluprost treatment. Measurements were repeated 2, 6 and 12 weeks after change of medication.
Results: No statistically significant differences in IOP were observed 2, 6, and 12 weeks after switching to preservative-free tafluprost. Mean IOP at baseline was 16.4 mmHg (SD 2.9), after 2 weeks 16.2 mmHg (2.8), after 6 weeks 16.2 (2.6), and after 12 weeks 16.3 mmHg (2.3). Mean tear osmolarity decreased significantly from 315.7 mOsm/L (SD 15.1) at baseline to 308.0 ± 14.4 mOsm/L (P = 0.002), 301.7 ± 14.5 mOsm/L (P < 0.001), and 302.0 ± 9.9 mOsm/L (P < 0.001) 2, 6, and 12 weeks after changing medication to preservative-free tafluprost, respectively. Tear osmolarity was lower in 37 eyes (61.7%) after 2 weeks, in 46 eyes (76.7%) after 6 weeks, and in 49 eyes (81.7%) after 12 weeks (P < 0.005; t-test). At baseline corneal fluorescein staining was observed in 43 eyes (71.7%), after 2 weeks in 34 eyes (56.7%), after 6 weeks in 12 eyes (20.0%), and after 12 weeks in 7 eyes (11.7%) (P < 0.005; McNemar test). Mean TBUT increased from 3.7 seconds (SD 1.1) at baseline to 4.1 seconds (SD 1.0) at week 2, 5.2 seconds (SD 1.5) at week 6, and 6.5 seconds (SD 1.5) at week 12 (P < 0.001; t-test). The number of patients expressing discomfort with latanoprost diminished from 30 (100%) at baseline, to 19 (63.3%) after week 2, and to 11 (36.6%) (P < 0.05; McNemar test) after 12 weeks.
Conclusion: Preservative-free tafluprost is better tolerated than BAK-containing latanoprost, showing lower tear osmolarity levels while maintaining effective IOP control.

Keywords: glaucoma, preservatives, tafluprost, osmolarity, intraocular pressure, prostaglandin analogs, BAK, tolerability

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.